• Home
  • Study Details
By physician referral or invitation only

APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Protocol

The purpose of this study is to assess the efficacy as well as safety and tolerability of a new drug called padsevonil that will be given in one of 3 different doses in addition to your current epilepsy treatment that may consist of 1-3 antiepileptic drugs. The study also aims to see how safe padsevonil is compared to placebo and how well your body can tolerate it.

Age & Gender

  • 1 years ~ 21 years
  • Male, Female

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical

Study Topics

Cancer (Pediatric Cancers)

IRB Number

17-3196

ClinicalTrials.gov

NCT03155620

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research